402 related articles for article (PubMed ID: 30268467)
1. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Jaine R; Kvizhinadze G; Nair N; Blakely T
Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Jaine R; Kvizhinadze G; Nair N; Blakely T
Lung Cancer; 2020 Jun; 144():99-106. PubMed ID: 32317183
[TBL] [Abstract][Full Text] [Related]
3. Impact of low-dose CT screening for lung cancer on ethnic health inequities in New Zealand: a cost-effectiveness analysis.
McLeod M; Sandiford P; Kvizhinadze G; Bartholomew K; Crengle S
BMJ Open; 2020 Sep; 10(9):e037145. PubMed ID: 32973060
[TBL] [Abstract][Full Text] [Related]
4. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
[TBL] [Abstract][Full Text] [Related]
8. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
10. Colorectal Cancer Screening: How Health Gains and Cost-Effectiveness Vary by Ethnic Group, the Impact on Health Inequalities, and the Optimal Age Range to Screen.
McLeod M; Kvizhinadze G; Boyd M; Barendregt J; Sarfati D; Wilson N; Blakely T
Cancer Epidemiol Biomarkers Prev; 2017 Sep; 26(9):1391-1400. PubMed ID: 28626068
[No Abstract] [Full Text] [Related]
11. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Lung Cancer Screening in Canada.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review.
Raymakers AJN; Mayo J; Lam S; FitzGerald JM; Whitehurst DGT; Lynd LD
Appl Health Econ Health Policy; 2016 Aug; 14(4):409-418. PubMed ID: 26873091
[TBL] [Abstract][Full Text] [Related]
15. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
17. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V; Cohen JT; van Klaveren D; Soeteman DI; Wong JB; Neumann PJ; Kent DM
Ann Intern Med; 2018 Feb; 168(3):161-169. PubMed ID: 29297005
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
Tomonaga Y; Ten Haaf K; Frauenfelder T; Kohler M; Kouyos RD; Shilaih M; Lorez M; de Koning HJ; Schwenkglenks M; Puhan MA
Lung Cancer; 2018 Jul; 121():61-69. PubMed ID: 29858029
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
Zhao Z; Gu S; Yang Y; Wu W; Du L; Wang G; Dong H
BMC Cancer; 2024 Jan; 24(1):73. PubMed ID: 38218803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
